Report cover image

Gynecological Cancer Drugs Market By Therapeutic Modality (Chemotherapy, Targeted Therapy, Hormonal Therapy), By Indication (Cervical Cancer, Uterine Cancer, Ovarian Cancer, Vaginal & Vulvar Cancer): Global Opportunity Analysis and Industry Forecast, 2020

Publisher Allied Market Research
Published Apr 01, 2022
Length 190 Pages
SKU # ALMR17334243

Description

Gynecological Cancer Drugs Market By Therapeutic Modality (Chemotherapy, Targeted Therapy, Hormonal Therapy), By Indication (Cervical Cancer, Uterine Cancer, Ovarian Cancer, Vaginal & Vulvar Cancer): Global Opportunity Analysis and Industry Forecast, 2020-2030

Cancer refers to a specific group of disorders that lead to abnormal cell growth within any part of the body. This growth may even spread to other body parts. Cancer is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female. Gynecological cancers include cancer in the uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle &tissue supporting the uterus.

The key factors that drive the market growth include, the high incidence of gynecological cancers, growth in the importance of targeted drug therapies, an increase in investment from government, public, &private sectors for cancer treatment, and a surge in the number of product approval for gynecological cancer drugs drive the market growth. However, the high cost of drug development and the threat of failure & adverse effects of cancer drug therapy on a patient’s body restrain this growth. The advancement of cancer drug research and the advent of personalized medicine approaches are expected to provide numerous opportunities for market growth during the forecast period.

The gynecological cancer drugs market is segmented into therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pneumonia testing market analysis from 2020 to 2030 to identify the prevailing pneumonia testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pneumonia testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pneumonia testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments


By Indication

Cervical Cancer
Uterine Cancer
Ovarian Cancer
Vaginal Vulvar Cancer

By Therapeutic Modality

Chemotherapy
Targeted Therapy
Hormonal Therapy

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

APOTEX INC
ASTRAZENECA PLC
BRISTOL-MYERS SQUIBB COMPANY
ELI LILLY AND COMPANY
F. HOFFMANN-LA ROCHE LTD
GLAXOSMITHKLINE PLC
MERCK & CO., INC
NOVARTIS AG
PFIZER INC
TEVA PHARMACEUTICAL INDUSTRIES LTD

Table of Contents

190 Pages
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY
4.1 Overview
4.1.1 Market size and forecast
4.2 Chemotherapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Targeted Therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Hormonal Therapy
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Cervical Cancer
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Uterine Cancer
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Ovarian Cancer
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Vaginal & Vulvar Cancer
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Therapeutic Modality
6.2.3 North America Market size and forecast, by Indication
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Therapeutic Modality
6.2.4.1.2 Market size and forecast, by Indication
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Therapeutic Modality
6.2.4.2.2 Market size and forecast, by Indication
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Therapeutic Modality
6.2.4.3.2 Market size and forecast, by Indication
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Therapeutic Modality
6.3.3 Europe Market size and forecast, by Indication
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Therapeutic Modality
6.3.4.1.2 Market size and forecast, by Indication
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Therapeutic Modality
6.3.4.2.2 Market size and forecast, by Indication
6.3.4.3 U.K.
6.3.4.3.1 Market size and forecast, by Therapeutic Modality
6.3.4.3.2 Market size and forecast, by Indication
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Therapeutic Modality
6.3.4.4.2 Market size and forecast, by Indication
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Therapeutic Modality
6.3.4.5.2 Market size and forecast, by Indication
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Therapeutic Modality
6.3.4.6.2 Market size and forecast, by Indication
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Therapeutic Modality
6.4.3 Asia-Pacific Market size and forecast, by Indication
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Therapeutic Modality
6.4.4.1.2 Market size and forecast, by Indication
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Therapeutic Modality
6.4.4.2.2 Market size and forecast, by Indication
6.4.4.3 Australia
6.4.4.3.1 Market size and forecast, by Therapeutic Modality
6.4.4.3.2 Market size and forecast, by Indication
6.4.4.4 India
6.4.4.4.1 Market size and forecast, by Therapeutic Modality
6.4.4.4.2 Market size and forecast, by Indication
6.4.4.5 South Korea
6.4.4.5.1 Market size and forecast, by Therapeutic Modality
6.4.4.5.2 Market size and forecast, by Indication
6.4.4.6 Rest Of Asia Pacific
6.4.4.6.1 Market size and forecast, by Therapeutic Modality
6.4.4.6.2 Market size and forecast, by Indication
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Therapeutic Modality
6.5.3 LAMEA Market size and forecast, by Indication
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Therapeutic Modality
6.5.4.1.2 Market size and forecast, by Indication
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Therapeutic Modality
6.5.4.2.2 Market size and forecast, by Indication
6.5.4.3 South Africa
6.5.4.3.1 Market size and forecast, by Therapeutic Modality
6.5.4.3.2 Market size and forecast, by Indication
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Therapeutic Modality
6.5.4.4.2 Market size and forecast, by Indication
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 APOTEX INC
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 ASTRAZENECA PLC
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 BRISTOL-MYERS SQUIBB COMPANY
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 ELI LILLY AND COMPANY
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 F. HOFFMANN-LA ROCHE LTD
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 GLAXOSMITHKLINE PLC
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 MERCK & CO., INC
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 NOVARTIS AG
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 PFIZER INC
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 TEVA PHARMACEUTICAL INDUSTRIES LTD
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 2. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR CHEMOTHERAPY, BY REGION, 2020-2030 ($MILLION)
TABLE 3. GYNECOLOGICAL CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 4. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR TARGETED THERAPY, BY REGION, 2020-2030 ($MILLION)
TABLE 5. GYNECOLOGICAL CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 6. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR HORMONAL THERAPY, BY REGION, 2020-2030 ($MILLION)
TABLE 7. GYNECOLOGICAL CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 9. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR CERVICAL CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 10. GYNECOLOGICAL CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 11. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR UTERINE CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 12. GYNECOLOGICAL CANCER DRUGS MARKET FOR UTERINE CANCER, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 13. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR OVARIAN CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 14. GYNECOLOGICAL CANCER DRUGS MARKET FOR OVARIAN CANCER, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR VAGINAL & VULVAR CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 16. GYNECOLOGICAL CANCER DRUGS MARKET FOR VAGINAL & VULVAR CANCER, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 17. GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 19. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 20. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21. U.S. GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 22. U.S. GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 23. CANADA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 24. CANADA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 25. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 26. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 27. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 28. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 29. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 30. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 31. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 32. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 33. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 34. U.K. GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 35. U.K. GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 36. ITALY GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 37. ITALY GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 38. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 39. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 40. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 41. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 42. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 43. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 44. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 45. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 46. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 47. CHINA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 48. CHINA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 49. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 50. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 51. INDIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 52. INDIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 53. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 54. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 55. REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 56. REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 57. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 58. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 59. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 60. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 61. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 62. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 63. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 64. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 65. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 66. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
TABLE 67. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 68.APOTEX INC: COMPANY SNAPSHOT
TABLE 69.APOTEX INC: OPERATING SEGMENTS
TABLE 70.APOTEX INC: PRODUCT PORTFOLIO
TABLE 71.APOTEX INC: NET SALES,
TABLE 72.APOTEX INC: KEY STRATERGIES
TABLE 73.ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 74.ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 75.ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 76.ASTRAZENECA PLC: NET SALES,
TABLE 77.ASTRAZENECA PLC: KEY STRATERGIES
TABLE 78.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 79.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 80.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 81.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,
TABLE 82.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 83.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 84.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 85.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 86.ELI LILLY AND COMPANY: NET SALES,
TABLE 87.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 88.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 89.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 90.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 91.F. HOFFMANN-LA ROCHE LTD: NET SALES,
TABLE 92.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
TABLE 93.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 94.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 95.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 96.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 97.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 98.MERCK & CO., INC: COMPANY SNAPSHOT
TABLE 99.MERCK & CO., INC: OPERATING SEGMENTS
TABLE 100.MERCK & CO., INC: PRODUCT PORTFOLIO
TABLE 101.MERCK & CO., INC: NET SALES,
TABLE 102.MERCK & CO., INC: KEY STRATERGIES
TABLE 103.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 104.NOVARTIS AG: OPERATING SEGMENTS
TABLE 105.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 106.NOVARTIS AG: NET SALES,
TABLE 107.NOVARTIS AG: KEY STRATERGIES
TABLE 108.PFIZER INC: COMPANY SNAPSHOT
TABLE 109.PFIZER INC: OPERATING SEGMENTS
TABLE 110.PFIZER INC: PRODUCT PORTFOLIO
TABLE 111.PFIZER INC: NET SALES,
TABLE 112.PFIZER INC: KEY STRATERGIES
TABLE 113.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 114.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
TABLE 115.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 116.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES,
TABLE 117.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION
FIGURE 2.GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030
FIGURE 3.GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.GYNECOLOGICAL CANCER DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.GYNECOLOGICAL CANCER DRUGS MARKET,BY THERAPEUTIC MODALITY,2020(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HORMONAL THERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
FIGURE 16.GYNECOLOGICAL CANCER DRUGS MARKET,BY INDICATION,2020(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF UTERINE CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OVARIAN CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF VAGINAL & VULVAR CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
FIGURE 21.GYNECOLOGICAL CANCER DRUGS MARKET BY REGION,2020
FIGURE 22.U.S. GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 23.CANADA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 24.MEXICO GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 25.GERMANY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 26.FRANCE GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 27.U.K. GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 28.ITALY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 29.SPAIN GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 30.REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 31.JAPAN GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 32.CHINA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 33.AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 34.INDIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 35.SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 36.REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 37.BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 38.SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 39.SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 40.REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45.COMPETITIVE DASHBOARD
FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 47.APOTEX INC.: NET SALES ,($MILLION)
FIGURE 48.ASTRAZENECA PLC.: NET SALES ,($MILLION)
FIGURE 49.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ,($MILLION)
FIGURE 50.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
FIGURE 51.F. HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
FIGURE 52.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
FIGURE 53.MERCK & CO., INC.: NET SALES ,($MILLION)
FIGURE 54.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 55.PFIZER INC.: NET SALES ,($MILLION)
FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES ,($MILLION)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us